| 1 | Ordinary | Adoption of financial statements for the year ended 31 March 2023 |  |
| 2 | Ordinary | Declare final dividend of Rs. 0.1 per equity share of face value of Rs. 1.0 for FY23 | |
| 3 | Ordinary | Reappoint Pranav Choksi (DIN: 00001731) as Director, liable to retire by rotation | |
| 4 | Ordinary | Reappoint Dr. Bal Ram H. Singh (DIN: 06918085) as Non-Executive Non-Independent Director, liable to retire by rotation |  |
| 5 | Ordinary | Ratify remuneration of Rs. 100,000 payable to Kale & Associates as cost auditors for FY24 | |
| 6 | Special | Approve continuation of Jayesh P. Chokshi (DIN: 00001729 as Chairperson and Managing Director on attaining seventy years of age on 29 March 2024 | |
| 7 | Special | Approve continuation of Gopal M Daptari (DIN: 07660662) as Independent Director on attaining seventy-five years of age on 29 October 2024 | |
| 8 | Special | Approve Gufic Biosciences Ltd Employee Stock Option Plan 2023 under which 500,000 stock options can be granted | |
| 9 | Special | Approve grant of Gufic Biosciences Ltd Employee Stock Option Plan 2023 to employees of subsidiaries and/or associates of the company | |
| 10 | Special | Approve preferential issue of upto 3,333,000 equity shares at Rs. 300.0 each aggregating to Rs. 999.9 mn to Motilal Oswal Financial Services Limited | |
Sept. 29, 2023, 3:30 p.m.